Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-054711
Filing Date
2025-04-16
Accepted
2025-04-16 16:05:18
Documents
20
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A crsp-20250416.htm   iXBRL DEF 14A 3011289
2 GRAPHIC img170270027_0.jpg GRAPHIC 87689
3 GRAPHIC img170270027_1.jpg GRAPHIC 66170
4 GRAPHIC img170270027_2.jpg GRAPHIC 640791
5 GRAPHIC img170270027_3.jpg GRAPHIC 544472
6 GRAPHIC img170270027_4.jpg GRAPHIC 573797
7 GRAPHIC img170270027_5.jpg GRAPHIC 1000094
8 GRAPHIC img170270027_6.jpg GRAPHIC 1419671
  Complete submission text file 0000950170-25-054711.txt   15428018

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250416.xsd EX-101.SCH 7548
22 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250416_htm.xml XML 613494
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37923 | Film No.: 25842746
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)